Title: Perioperative use of NSAID might prevent early relapses in breast and other cancers: An upstream approach

Abstract:

A bimodal pattern of hazard of relapse among early stage breast cancer patients has been identified in multiple databases from US, Europe and Asia. We are studying these data to determine if this can lead to new ideas on how to prevent relapse in breast cancer. Using computer simulation and access to a very high quality database from Milan for patients treated with mastectomy only, we proposed that relapses within 3 years of surgery are stimulated somehow by the surgical procedure. Most relapses in breast cancer are in this early category. Retrospective data from a Brussels anesthesiology group suggests a plausible mechanism. Use of ketorolac, a common NSAID analgesic used in surgery was associated with far superior disease-free survival in the first 5 years after surgery. The expected prominent early relapse events in months 9-18 are reduced 5-fold. Transient systemic inflammation accompanying surgery (identified by IL-6 in serum) could facilitate angiogenesis of dormant micrometastases, proliferation of dormant single cells, and seeding of circulating cancer stem cells (perhaps in part released from bone marrow) resulting in early relapse and could have been effectively blocked by the perioperative anti-inflammatory agent. If this observation holds up to further scrutiny, it could mean that the simple use of this safe, inexpensive and effective anti-inflammatory agent at surgery might eliminate early relapses. We suggest this would be most effective for triple negative breast cancer and be especially valuable in low and middle income countries. Similar bimodal patterns have been identified in other cancers suggesting a general effect.

Biography:

Michael Retsky (PhD in Physics from University of Chicago 1974) made a career change to cancer research 35 years ago. He is on staff at Harvard TH Chan School of Public Health. He was Prof of Biology at University of Colorado - Colorado Springs. He was Visiting Prof at several universities. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. Retsky is Editor of a Nature/Springer book on the breast cancer project that was published in 2017. He was the first person to use what is now called metronomic adjuvant chemotherapy and was a founder and on the Board of Directors of the Colon (now Colorectal) Cancer Alliance. He has published more than 100 papers in physics and cancer. Most recent publication is Retsky et al, Breast Cancer and the Black Swan - available open access on PubMed.

Title: Supportive Care ? : The Patient Care ?

Abstract:

What is supportive care?
Support care means all care and support that can be offered to a person suffering from cancer, alongside specific treatments to cure his diseases such as chemotherapy, radiotherapy, and surgery. They aim to reduce the impact of disease and treatment. For this, a team of professionals specialized in very different fields puts their skills available to patients to help them cope with this difficult time. The support can be offered care during and after treatment of
the disease but also when the cancer treatments have no effect. They adapt to the needs of patients and their families.
What needs do they meet?
The disease affects all aspects of daily life.
The needs that may occur are numerous.
support care can meet some of these needs:
• primarily to control the symptoms related to the disease or its
treatment
• in case of physical or psychological suffering
• to break the isolation
• to learn to live with the physical consequences imposed sometimes
disease
• to resume the normal course of his life and benefit from the best
possible living conditions, and that whatever the chances of
recovery
• for many other reasons, each patient with the needs of its own.
Being listened, to feel supported
Prevent pain
Food: a pleasure and a need
Staying in tune with her body
A new impetus to social life

Biography:

Professional experience in oncology circles, supported by multiple collaborations with major hospitals, allowed LOUIS CAZE to benefit from the reference frame as an Expert Support Care. First, Specialist lymphatic, muscular and circulatory LOUIS CAZE makes the total body approach his chosen field. It captures the benefits of physical-mental balance in the treatment of chronic diseases and specializes in supportive care dedicated to cancer diseases. His collaboration with renowned organizations such as the Institute Gustave Roussy, was punctuated with exceptional professional and human experience. LOUIS CAZE is involved in implementing a comprehensive approach to a cancer patient, in a real project of care that optimizes patient's quality of life, ensuring the different key aspects of health: the well physical and psychological, but also the entire social and family interactions. After these experiences, LOUIS CAZE works for the development of Support Care, including the management of pain and psychology.

Title: Oncolytic viruses and cancer

Abstract:

The future of cancer drugs is very promising: RNA therapies, bacteria, and oncolytic viruses are between the drugs oncologists have or will have to treat their patients. About the last one, since the 1950s scientists began testing interferon-sensitive viruses with natural oncotropism, and in the 1990s, they have been modifying viruses and bacteria to develop tumor selectivity and they can reprogram viruses into oncolytic vectors by combining three types of modification: targeting, arming and shielding. Currently, oncolytic viruses are powerful new therapeutic agents in cancer therapy and include viruses found in nature and viruses modified in the laboratory to reproduce efficiently in cancer cells without harming healthy cells. One oncolytic virus, T- VEC, a genetically modified form of a herpes virus for treating melanoma has been approved by the Food and Drug Administration. Another approved oncolytic virus is Rigvir in Latvia and Georgia for melanoma, pancreatic, kidney, and lung cancer. Laboratory studies conducted at the Memorial Sloan-Kettering Cancer Center suggest too triple-negative breast cancer might respond to treatment with an oncolytic agent and many other types of cancer like brain cancer can be treated with a new approach. Studies are currently ongoing about the compatibility between oncolytic virotherapy, chemotherapy like paclitaxel for breast cancer checkpoint inhibitors in patients with melanoma. In general, oncolytic virus treatment has a safety profile and the side effects associated with T-VEC include chills, flu-like symptoms, injection site pain, nausea, and fever. The main mechanism used by the virus to kill tumors according to consensus involves an important immune component to the response. On the other hand, some of the challenges of virotherapy include systemic delivery, intratumoral spread, and improving anti-tumor versus anti-virus immune response and many trials are ongoing to address it and many other points of interest.

Biography:

Robens Molaire Saintil is a medical doctor since 2000. He did residence in internal medicine in Padre Billini Hospital and clinical Oncology in Heriberto Pieter Oncology Institute, Dominican Republic. He has a master's in hospital management in Madrid, Spain, and a Ph.D. in nutritional science at the Atlantic International University of USA. To be updated, he continues with MEDSCAPE and NCCN for continuing medical education since 2016 and has actually 130 credits. Now, he works at a provincial hospital in Monte Plata, Dominican Republic. He is very interested in investigations on this topic.

Title: State of the art management of Radioactive-Iodine Refractory Differentiated Thyroid Cancer (RAI-R DTC)

Abstract:

Introduction: The treatment options for patients with radioactive iodine refractory differentiated thyroid cancer include observation, multi-tyrosine kinase inhibitors (MTKIs), and traditional chemotherapy. Appropriate initial treatment with MTKI is challenging in clinical practice that the benefits outweigh the risk of any adverse events. Treatment strategies for Radioactive-Iodine Refractory Differentiated Thyroid Cancer: The activation of multiple downstream VEGFR signaling pathways, oncogenic mutated kinases (e.g. BRAF mutations), rearrangements of RET, ALK, NTRK, and TERT promoter mutations are molecular mechanisms involved in RAI-R DTC. MTKIs demonstrated the clinical benefits of either progression-free survival (11 to 18 months) and response rate (24-63%). Sorafenib and lenvatinib were approved by the FDA for the treatment of RAI-R DTC. However, up to 60% of patients with MTKIs required a dose reduction due to adverse events (AEs). The most frequent AEs are hypertension, diarrhea, weight loss, mucositis, fatigue,hand-foot syndrome, alopecia, and diarrhea. Therefore, close monitoring for disease progression and TSH-suppressive therapy is an appropriate treatment for those patients with asymptomatic metastatic disease or slow-growing tumors. Initiation of treatment with MTKIs should be considered in symptomatic disease or a rapidly growing tumor.
Conclusions: MTKIs demonstrate a promising approach. Sorafenib and lenvatinib have been approved by the FDA for the treatment of RAI-R DTC. However, multidisciplinary evaluation for the adjustment made to take account of clinical benefits and risks should be performed before initiating MTKIs regarding potential toxicities.

Biography:

Dr. Prasongsook has completed the Thai Board of Medical Oncology from Ramathibodi Hospital, Bangkok, Thailand, then a postdoctoral research fellowship in Medical Oncology at Mayo Clinic, and a master's degree of Clinical Translational Science Program from Mayo Graduate School, Rochester, MN, USA. The current position is an assistant professor in the Medical Oncology unit at Phramongkutklao Hospital, Bangkok, Thailand. Research interests include all areas of care related to endocrine malignancies, with focusing on thyroid cancer, lung cancer, and the nutraceutical approach in cancer treatment.

Title: Cancer Epidemiology in Pakistan: A Step Towards First National Cancer Registry

Abstract:

Cancer statistics is a fundamental requirement for planning and implementation of cancer controls programs. In Pakistan no national cancer epidemiological data have been published. In Pakistan cancer incidence and mortality are rapidly increasing. The reasons are not simple to establish but aging and population growth are couple of them. The lack of national level information systems on health indicators in Pakistan means that estimation methods are required.

In this study national level cancer statistics have been made using hospital data throughout the country from January 2015 to December 2017. A total of 102,022 cancer patients were reported to the specialized cancer hospitals throughout the country.

Secondary data analysis shows 57,213 (56%) females and 44,809 (44%) males. Overall the leading cancer type was breast cancer which is 22.6% in the population followed by oral cavity 8.3%, colorectal 4.4%, CNS 4.1%, NHL 3.9%, lung 3.9%, esophagus 3.8%, ovary 3.7%, liver 3.6%, leukemia 3.1% and others 38.70%. Among males the leading cancer is oral cavity 12.1% followed by lung 6.6% and colorectum 6.3% while in females the leading cancer was breast cancer 39.5% followed by ovary 6.6% and oral cavity 5.3%. Among the total cancer patients children were (2,307) 2%, adolescents (4,569) 4%, adults (21,504) 21%, middle aged (42,383) 42% and senior citizens (31,261) 31%. Region wise cancer distribution were, in Islamabad total cases 1,960 males 682 (35%) and females 1,278 (65%). Punjab 45,105 males 17,199 (38%) and females 27,906 (62%). Sindh 28,753 males 14,021 (49%) females 14,732 (51%). Khyber Pakhtunkhwa 12,055 males 5,635 (47%) and females 6,420 (52%).  Balochistan 6,728 males 3,379 (51%) and females 3,349 (49%)

Cancer is still a huge health issue. Compromising quality of life and economic implications in both developed and low middle income countries like Pakistan. Currently no reliable data is available regarding prevalence, morbidity and mortality of various cancers. This could be due to lack of national cancer information system. Although cancer registration been developed and are functional but they operate on institutionalized basis. For the deterrence in the prevalence of disease the health care authorities must ponder over the current situation seriously by developing a proper centralized institute an organized system and its implementation. 

Biography:

Dr Nauman Arif is a PhD scholar in Cancer epidemiology and working as a faculty member in the Institute of Public Health and Social Sciences, Khyber Medical University, Peshawar (the only public sector medical university in Khyber Pakhtunkhwa province, Pakistan), since May 2018. Earlier I was working as a trainee medical officer at Institute of Public Health and Social Sciences, Khyber Medical University, Peshawar, Pakistan from January 2017 to May 2018. Currently I am teaching to MPH, MSC Epi & Bio, MHR and CHR. I am also course coordinator MS Epidemiology Program. I have just completed my masters in epidemiology and biostatistics course (MSC Epi & Bio) from a very highly reputed public sector medical university (Khyber Medical University) in Pakistan. Earlier, I completed masters in public health (MPH) from the above mentioned medical university. I also did Doctor of Pharmacy degree from the highly reputed university in Pakistan.

Title: The effectiveness of systemic treatment of breast cancer depending on the body weight index using levocarnitine.

Abstract:

The prevalence of breast cancer (BMD) in the world in general and in Ukraine is steadily increasing. Epidemiological, experimental, and clinical studies have shown that metabolic disturbances associated with body mass index (BMI)> 30 kg / m2 increase the risk of occurrence and worsen the clinical course of breast cancer. Thus, in patients with obesity, a decrease in the sensitivity of the tumor to systemic antitumor therapy, an increase in the frequency of postoperative complications, and a decrease in the rates of general and non-recurrent survival. The aim of the study was to improve the results of neoadjuvant systemic antitumor therapy in breast cancer patients with abdominal obesity (BMI greater than 30 kg / m²) by administering levocarnitine in combination with NSAT for the correction of metabolic disorders as the main pathogenetic part of obesity.

For the study used a retrospective study between 2010 and 2014 three hundred patients (prevalence of 12.4% which is 100 thousand. population in the Dnipropetrovsk region) with BMI> 30 kg / m², morphologically verified diagnosis of different forms of breast cancer and all stages (I- IV). Subsequently, a group of comparisons with abdominal obesity BMI> 30kg / m² with a definite molecular subtype of tumor, levels of expression of estrogen receptor ER, progesterone PgR, Her-2 / neu, Ki-67 proliferation index was formed. The observation group of patients with breast cancer and BMI> 30kg / m² was formed in the period from 2014 to 2018 due to prospective observation of "case-control". Thus, the study involved 108 patients aged 32 to 76 years (mean age (58 ± 2). With nodal breast cancer II-III stage. As a result of the randomization of all patients (n = 108) on breast cancer with BMI> 30 kg / m², depending on the appointment of levocarnitine during NSAT, were divided into 2 groups: comparison and observation. In the comparison group, patients (n = 58) with BMI> 30 kg / m² patients with breast cancer who did not receive levocarnitine during NSPT, and in the observation group - patients (n = 50) on breast cancer with BMI> 30 kg / m² who received levocarnitine during NIST. For the first time, on the basis of a comprehensive analysis of the results, it was established that the appointment of levocarnitine in patients with breast cancer with BMI> 30 kg / m² contributes to increasing the clinical and morphological efficacy of neoadjuvant systemic antitumor therapy (NSAT). It was found that in patients with breast cancer with BMI> 30 kg / m², who were prescribed levocarnitine, organ surgery surgical interventions were significantly more frequent. The algorithm of diagnosis and treatment of breast cancer in patients with obesity has been developed and scientifically substantiated. A theoretical generalization of modern scientific data on the influence of metabolic disorders that are characteristic of obesity, on carcinogenesis of breast cancer is carried out. A complex (integrated) scheme of mechanisms of influence of molecular disorders associated with obesity, on the carcinogenesis of breast cancer is developed. It is determined that the leading role in carcinogenesis is played by: abdominal obesity, hyperglycemia, dyslipidemia, and chronic subclinical inflammation. The carcinogenic effect of these factors is realized due to the ability of the adipose tissue of the mammary glands to increase the local concentration of estrogen by peripheral aromatization of androgens, the mitogenic effect of metabolic disorders on the epithelium of the mammary gland. It was established that in patients with breast cancer with BMI greater than 30 kg / m² receiving levocarnitine, a statistically significant increase in the number of cases of clinically complete regression of tumors was observed at 12.8% (5.2% vs. 18.0%; p <0.05) and a partial regression of 13.1% (6.9% vs. 20.0%, p <0.05). Lowering the frequency of breast cancer progressing on the background neoadjuvant systemic anticancer therapy in patients with a group of observations by 44.3% compared with women with the comparison group (16.0 vs. 60.3%, p <0.05). According to the results of analysis of the parameters of cellular, humoral immunity (CD3, CD4, CD8, IgG, IgM, IgA) and proinflammatory cytokines (IL-6, TNFα), there was a decrease in the number of patients with breast cancer with BMI greater than 30 kg / m² in (NSAT) Levocarnitine with regression rates was used for juvenile systemic anticancer therapy, namely: for CD3, which was 41.4%; for CD4, which was 50.0%; for CD8, which was 23.5%; for IgG, which was 40.4%; for IgM, which equaled 48.7%; for IgA, which was 44.4%; for IL-6, which was 51.1%; for CD3, which was 50.0%, respectively. It was found that the appointment of levocarnitine in patients with breast cancer with BMI greater than 30 kg / m² during preoperative systemic antitumor therapy increases its efficacy compared with patients who received neoadjuvant systemic antitumor therapy. Registered increase in the incidence of clinically significant responses (CR + PR) for the treatment in 63.2% of patients in the observation group who were administered in the treatment Levocarnitine (28.0% vs. 12.1%, p <0.05) compared with a comparison group. Based on the research, it was proved that in the group of patients with BMI greater than 30 kg / m² receiving levocarnitine, there was a statistically significant increase in the frequency of performing functionally justified organoleptic operations by 53.8% compared with the comparison group (27.1% vs. 10.9%; p <0.05). Also, the administration of levocarnitine during neoadjuvant systemic antitumor therapy increases the number of cases of complete morphological regression (V degree of curative pathomorphosis) by 77.8% in the observation group compared to patients from the comparison group (18.8% vs. 3.6%; p <0.05). Found that neoadjuvant systemic anticancer therapy in breast cancer patients with a BMI over 30 kg / m2 does not affect the degree of differentiation and histological type of tumor and the expression of Her2 / neu (p> 0.05). After neoadjuvant systemic anticancer therapy, regardless of the purpose levocarnitine in decreasing residual tumor cell proliferation index (Ki-67) and increased incidence of Luminal A molecular type of breast cancer. This may indicate that neoadjuvant systemic antitumor therapy leads to the death of the most aggressive tumor clones. It was investigated that the appointment of levocarnitine in patients with breast cancer with BMI greater than 30 kg / m² does not affect the indicators of general and non-recurrent survival, with observation (18,1 ± 1,5) months. These data are in the basis for integrated assessment and in-depth understanding of the negative impact of abdominal obesity associated with impaired carbohydrate and fat metabolism in carcinogenesis and criteria can be aggressive course of breast cancer and adverse prognostic factors. Correction of metabolic disorders caused by obesity, eliminates their negative impact on breast cancer carcinogenesis and prognosis of the disease, allowing you to customize and personalize the treatment strategy for breast cancer patients with a BMI> 30 kg / m² and improve its results. When planning treatment in patients with breast cancer advisable to consider the presence of symptoms and diseases that are unique and are associated with obesity where BMI over 30 kg / m², as the presence of disorders of carbohydrate and fat metabolism and hypertension is an indication for additional surveys aimed at identifying metabolic disorders with the aim of individualizing and personalizing tactics of systemic antitumor therapy. Against neoadjuvant systemic anticancer therapy for breast cancer patients with a BMI over 30 kg / m² to be additionally administered drugs that increases the incidence of complete morphological regression. This drug is levocarnitine in therapeutic doses (1500 mg / day), which has proven to be an effective means to increase the number of cases of clinically relevant responses (CR + PR) to the treatment. Analysis and systematization of the results of the study allowed to create algorithms of diagnosis and treatment from the standpoint of personalization and individualization, based on which there is a correlation dependence that can be used in the clinical practice of oncologic hospitals to improve the treatment of patients with breast cancer with BMI greater than 30 kg / m². Thus, the use of neoadjuvant systemic antitumor therapy in combination with levocarnitine contributes to an increase in the number of cases of objective clinical (complete regression and partial regression) and morphological (therapeutic paedomorphosis IV and V degree) tumor response to cytotoxic breast cancer therapy in patients with BMI> 30 kg / m² and frequency of organ-saving surgical interventions.

Keywords: breast cancer, obesity, neoadjuvant systemic antitumor therapy, body mass index> 30 kg / m², levocarnitine.

Biography:

Accossiat professor Department-of oncology and medical radiology, MD, PHD,MSo.
(more than 340 trials. Principal Investigator Bondarenko Igor) Municipal Institution “Dnipropetrovsk City Multi-field Clinical Hospital #4” of Dnipropetrovsk Regional Council”, Chemotherapy Department, State Institution “Dnipropetrovsk Medical Academy at the Ministry of Health of Ukraine”, Oncology and Medical Radiology Department. 31 Blizhnyaya Str., Dnepropetrovsk, 49102, Ukraine, 

Title: Combination Targeted and Immunotherapies in Solid Tumor Brain Metastases

Abstract:

An estimated 20% of all patients with cancer will develop brain metastases, with the majority of those occurring in patients with lung, breast and colorectal cancers, melanoma, and renal cell carcinoma. Brain metastases are thought to occur via seeding of circulating tumour cells into the brain microvasculature; within this unique microenvironment, tumour growth is promoted and the penetration of systemic medical therapies is limited.

Development of brain metastases remains a substantial contributor to overall cancer mortality in patients with advanced-stage cancer, as prognosis remains poor despite multimodal treatments and advances in systemic therapies, which include a combination of surgery, radiotherapy, chemotherapy, immunotherapy and targeted therapies. This has driven continued development of novel immunotherapies and targeted therapies that have higher bioavailability beyond the blood–tumour barrier, to further advances in radiotherapies and minimally invasive surgical techniques.

As these discoveries and innovations move from the realm of basic science to preclinical and clinical applications, future outcomes for patients with brain metastases are almost certain to improve. In this virtual presentation, we will explore combination trials in solid tumor brain metastases, highlighting the unmet needs in this patient population and underlining promising combination strategies. 

Biography:

Dr. Morganna Vance is a Medical Director within the Melanoma Medical Affairs division at Novartis US Oncology, currently overseeing the conduct of Phase II-III trials in melanoma brain metastases. Dr. Vance is a skin cancer specialist & former Medical Director of Community Practice at City of Hope, an internationally recognized Comprehensive Cancer Center. A recipient of the 2018 Melanoma Research Foundation Humanitarian Award, Dr. Vance contributes regularly as an invited speaker, serves on cancer prevention advisory boards, and is a skilled health policy analyst.

Title: The Beats Drop Cancer Free Music Therapy Clinic

Abstract:

Since my, 2015 Man of the Year campaign for the Leukemia and Lymphoma Society in the Bay Area, we have been on a mission to help Cancer patients beat this disease.  Originally, Beats Drop Cancer was my campaign to honor the most important person in my life, my grandmother. She was diagnosed with Breast Cancer and given 3 months to live. She tells her Doctor, F that!! Nazi death squads tried to kill me, this is just Cancer. She ended up living 7 and a half years longer because of her mental strength and will. It hit me that we can do so much more. We turned BDC is its own entity.  We became Beats Drop Cancer Inc. a 501 c(3) with the mission to use music as our primary tool to help cancer patients deal with the psychological fatigue and depression that comes along with chemotherapy. But since then we have learned so much more and evolved...

We began doing our research. For example,

Data Research

"A new study conducted by researchers from Duke University, MIT and Singapore's Nanyang Technological University shows that sound waves are capable of rapidly and efficiently separating circulating tumor cells (CTCs) from blood. CTCs are small pieces of tumor that break away and flow through the bloodstream. They contain a wealth of information including tumor type, physical characteristics and genetic mutations." 

http://dukecancerinstitute.org/news/sound-waves-could-provide-new-tool-fight cancer

"High intensity focused ultrasound (HIFU) is a treatment that aims to kill cancer cells with high frequency sound waves. HIFU doesn't pass through solid bone or air, so it's not suitable for every cancer.You have this treatment from a machine that gives off high frequency sound waves. These waves deliver a strong beam to a specific part of a cancer. The high intensity ultrasound beam is focused directly onto the cancer which heats the cells up and kills them." 

https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/other/high-intensity-focused-ultrasound-hifu

After finding this research, we knew we were on the right track. My wife and I both came from the Music Industry. So the pieces to this puzzle starting to come together. Then we took our knowledge of sound for Example, 

Ambisonics 

What is Ambisonics?

Ambisonics is a method for recording, mixing, and playing back three-dimensional 360-degree audio. It was invented in the 1970s but was never commercially adopted until recently with the development of the VR industry which requires 360° audio solutions.

The basic approach of Ambisonics is to treat an audio scene as a full 360-degree sphere of sound coming from different directions around a center point. The center point is where the microphone is placed while recording, or where the listener’s ‘sweet spot’ is located while playing back. 

What is Music Therapy?

"Music Therapy is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program.

Music Therapy is an established health profession in which music is used within a therapeutic relationship to address the physical, emotional, cognitive, and social needs of individuals. After assessing the strengths and needs of each client, the qualified music therapist provides the indicated treatment including creating, singing, moving to, and/or listening to music. Through musical involvement in the therapeutic context, clients' abilities are strengthened and transferred to other areas of their lives. Music therapy also provides avenues for communication that can be helpful to those who find it difficult to express themselves in words. Research in music therapy supports its effectiveness in many areas such as: overall physical rehabilitation and facilitating movement, increasing people's motivation to become engaged in their treatment, providing emotional support for clients and their families, and providing an outlet for expression of feelings." 

https://www.musictherapy.org/about/musictherapy/

We put these three theories together and realized we can not only help the mind, the body, and one's spirit, but we can attack those cancer cells. We have one of the top Sound Engineers on our team, Paul Breed. This is the evolution of Beats Drop Cancer Inc. The best part about all of this is this...we have secured a space to launch the very first Beats Drop Cancer Free Music Therapy and Wellness Clinic for Cancer in San Francisco. We open this October in conjunction with our open Air Gala this October 17, 2020. We know we are in a pandemic due to Covid-19.  That being said, Cancer did not just punch out and take a break. This is our way to do what we can to help Cancer patients fight and hopefully win their battle with Cancer. Thank you so much for reaching out to me and I hope my Abstract Submission is everything and more than you expected.  Please let me know if I am selected to speak. Let's harness to power of Sound and it's endless possibilities #BeatsDropCancer

Title: Nursing management of fever and neutropenia

Title: The Tyler Robinson Foundation: Providing Financial and Emotional Support for Pediatric Cancer Families

Abstract:

Kim Gradisher serves as executive director for the Tyler Robinson Foundation (TRF), the nonprofit organization of the GRAMMY Award-winning band Imagine Dragons, which is dedicated to strengthening families financially and emotionally as they cope with the tragedy of a pediatric cancer diagnosis by providing grants to offset out-of-pocket life expenses. In this capacity, Gradisher is responsible for overseeing all aspects of the foundation and its strategic operations. She works closely with TRF’s Board of Directors to meet goals and ensure that programming and staff members are aligned with the TRF mission and vision. Gradisher directs all strategic and operational planning, program operations and project management, community outreach, donor development, fundraising campaigns, marketing initiatives, and staff. She boasts more than a decade of experience in the non-profit sector, developing and executing key programs in positions supporting the Crohn’s and Colitis Foundation, Special Olympics Northern California and Nevada, and the Arthritis Foundation.
Gradisher holds a bachelor of science degree in recreational management from the University of Nevada Las Vegas and a certificate from Cornell University in women in leadership.

Biography:

Statement of the Problem: Families of children who are diagnosed with pediatric cancer are at a high risk of financial toxicity, which also causes an increase in emotional distress. Families must manage childcare, travel, and food during and after their children's treatments. The stresses of these factors on top of the tragedy of dealing with a pediatric cancer diagnosis can be devastating to the financial and emotional well-being of a family. These families require financial and emotional support during and after a child's treatment to attempt to reduce these stresses. Researchers have reported that 1/5 of cancer patients’ families reported losing more than 40% of their annual income due to work disruptions. Financial and emotional resources for families dealing with pediatric cancer beyond research is not as common as is required considering the need that exists. Methodology & Theoretical Orientation: The mission of The Tyler Robinson Foundation is to strengthen families financially and emotionally as they cope with the tragedy of a pediatric cancer diagnosis by offsetting out-of-pocket life expenses. We have provided financial resources in the form of grants and other programs to more than 1,500 families across the world, concentrating on the United States and Canada, since our founding in 2013. Interaction between staff and families also provide much needed emotional support. Our families have let us know that the financial relief that they receive has had a positive effect on their families and the amount of focus that they can place on their children. Conclusion and Significance: The Tyler Robinson Foundation has assisted families for 7 years to focus on the care of their children during pediatric cancer treatment while reducing financial stresses, which in turn provides some relief for their emotional distress. We intend to continue in our mission and expand beyond our current reach.

Title: Lung cancer SBRT calculation algorithm dosimetric comparison between AAA and AcurosXB in intensity modulated radiation therapy IMRT

Abstract:

This paper's purpose is to assess the accuracy of two Algorithms, Anisotropic Analytical Algorithm (AAA) and Acuros XB (AXB) used for dose calculation in the treatment planning system Eclipse TPS (Varian Medical Systems, Palo Alto, CA). Estimating conformity (CI) and homogeneity index (HI) using 6 MV photon energy implemented in true beam linear accelerator
Material and methods: CT series of 27 non-small cell lung cancer (NSCLC) patients treated with intensity-modulated radiation therapy (IMRT) technique. Complex cases planned for stereotactic radiation body radiosurgery (SBRT) treatment, using (AAA) algorithm. Then recalculate the same plans using the Acuros XB algorithm estimating the conformity index (CI) and homogeneity index (HI) for PTV using a dose-volume histogram (DVH) for both calculation algorithms were calculated.
Results: The results of the part of the clinical study showed no significant differences for the mean dose but different noticed in conformity index for the planning target volume (PTV) for both algorithms that was between (1.45±0.55) for AAA and (2.17±0.7) for Acuros XB however the Homogeneity Index difference (0.15±0.07) for AAA and (0.1±0.08) for across XB, the maximum dose for PTV are significantly differed about 2.3% to 4.5% between them.

Title: Program against Cancer in Niger

Abstract:

Worldwide, one in eight deaths is due to cancer. Projections based on the GLOBOCAN 2012 estimates predict a substantive increase in new cancer cases per year by 2035 in developing countries if preventive measures are not widely applied. According to the World Health Organization (WHO), millions of lives could be saved each year if countries made use of existing knowledge and the best cost-effective methods to prevent and treat cancer. Therefore, the aim of this study is to estimate a provisional budget against cancer in low and middle incomes countries, according to the GNI-PPP, the cancer incidence, and the population. Economically country classification is determining with the Gross national income (GNI), per capita, Purchasing power parity (PPP), according to the administrations of the International Monetary Fund (IMF), the World Bank (WB), and the Central Intelligence Agency (CIA). Cancer incidence data presented are based on the most recent data available at IARC. However, the population compares estimates from the US Bureau of the Census. The provisional budget is establishing among the guidelines developed by WHO for regional and national cancer control programs according to national economic development. The provisional budget against cancer is estimated to 21,824.998 (thousands of U.S $) for a population of 19,245,344 persons in Niger.

Biography:

Dr. El Hadji Seydou Mbaye was born in 1978 in Kaolack a region of Senegal. During 2008-2013, he earned his Ph.D. in Biology and Human Pathologies with the collaboration of the International Agency for Research on Cancer (IARC) /WHO, Lyon (France); 2006-2007: Master of Life and Health, Specialty Biology of microorganisms, Virology in Louis Pasteur University of Strasbourg (France); 2005-2006: Master of Life and Health, the option of Immuno-physiopathology in Louis Pasteur University of Strasbourg (France); 2004-2005: License of Biochemistry in Louis Pasteur University of Strasbourg (France); 2002-2004: General Degree in Sciences and Technologies in University of METZ (France). He was certified Grade 10/10 by the Federation International of Gynecology Obstetrics (FIGO), the Accreditation Council of Oncology in Europe (ACOE), the Institute Catalan of Oncology (ICO) for cervical cancer prevention. These credits were Recognized as Physician’s Recognition Award by the American Medical Association. He was awarded as International Outstanding Scientist Awards 2020. He was certified, by the United Nations, by IARC/WHO. He has published 1 Book with a style of philosophical story. Author of the World Program against Cancer in Low and Middle Incomes Countries, he is the lead author of more than 90 peer-reviewed research articles published in reputed journals. Dr. Mbaye is Editor in Chief of 4 journals, Editorial Board Member of 125 International Journals, and then he has Edited/Reviewed 191 peer-reviewed articles. He is a member of Allied Academies, associate membership of the World Society for Virology (WSV), and also, member of BCNet International Working Group, IARC/WHO. Dr. MBAYE has formed for free, more than 250 Healthcare Professionals for the techniques of cervical cancer screening in Senegal. He has screened for free more than 2000 women for cervical cancer in Senegal.